PUBLISHER: The Business Research Company | PRODUCT CODE: 1942611
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942611
Continuous renal replacement therapy (CRRT) is a form of dialysis that provides gradual, ongoing blood filtration to help regulate levels of fluids, electrolytes, and waste products in critically ill patients with acute kidney injury (AKI) who are hemodynamically unstable. It plays a crucial role in managing fluid overload in critically ill patients, particularly those who cannot tolerate rapid fluid removal through intermittent hemodialysis due to cardiovascular instability.
The primary products in the continuous renal replacement therapy market are systems and consumables. A continuous renal replacement therapy (CRRT) system is a specialized medical device utilized in treating critically ill patients with AKI or other renal conditions. It offers various renal and non-renal therapies using different modalities such as slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). These therapies are administered to adults, pediatrics, and neonates in various settings including hospitals, ambulatory care centers, and homecare setups.
Tariffs are impacting the continuous renal replacement therapy market by increasing costs for imported crtt machines, hemofilters, tubing sets, and dialysis consumables. These cost pressures have particularly affected system and consumables segments, with asia-pacific and europe experiencing higher exposure due to cross-border manufacturing and sourcing. Increased tariffs have raised procurement costs for hospitals and intensive care units and influenced purchasing decisions. However, tariffs have also encouraged local manufacturing, regional sourcing, and supply chain diversification, supporting long-term availability and resilience.
The continuous renal replacement therapy market research report is one of a series of new reports from The Business Research Company that provides continuous renal replacement therapy market statistics, including continuous renal replacement therapy industry global market size, regional shares, competitors with a continuous renal replacement therapy market share, detailed continuous renal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the continuous renal replacement therapy industry. This continuous renal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The continuous renal replacement therapy market size has grown rapidly in recent years. It will grow from $1.73 billion in 2025 to $1.92 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rising incidence of acute kidney injury in critical care, increasing icu admissions for sepsis and multi-organ failure, growing use of renal support therapies, expansion of critical care infrastructure, improved survival of critically ill patients.
The continuous renal replacement therapy market size is expected to see strong growth in the next few years. It will grow to $2.77 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to aging population with higher aki risk, increasing burden of critical illnesses, growing adoption of advanced renal support technologies, rising focus on individualized critical care treatment, expansion of intensive care capacity in emerging markets. Major trends in the forecast period include rising adoption of CRRT in intensive care units, increasing use of continuous therapies for hemodynamically unstable patients, growing demand for precision fluid and electrolyte management, expansion of CRRT use in pediatric and neonatal care, increasing preference for integrated CRRT systems and consumables.
The growing prevalence of chronic kidney disease (CKD) is expected to drive the expansion of the continuous renal replacement therapy (CRRT) market in the future. CKD is a long-term condition in which kidney function gradually declines, impairing the organ's ability to filter waste from the blood. This increase in CKD cases is largely attributed to factors such as lifestyle changes, an aging population, and higher rates of diabetes and hypertension. Continuous renal replacement therapy is commonly used to manage acute exacerbations or complications of CKD, helping to regulate fluid balance and remove metabolic waste continuously. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that more than 35.5 million adults in the United States-about 1 in 7-are affected by CKD. Alarmingly, nearly 90% of these individuals are unaware of their condition, highlighting the significant gap in early detection and awareness efforts in the U.S.
Leading companies in the continuous renal replacement therapy (CRRT) market are concentrating on developing advanced renal therapy solutions for dialysis patients, aiming to improve treatment effectiveness, enhance patient outcomes, and reduce complications linked to conventional dialysis methods. Unlike traditional dialysis, this therapy runs continuously-usually over a 24-hour period-and is gentler on the body, making it particularly suitable for patients with acute kidney injuries or severe medical conditions. For example, in January 2023, Peconic Bay Medical Center (PBMC), a U.S.-based healthcare facility offering emergency and surgical services, introduced a new renal therapy option for dialysis patients. This therapy is designed to offer greater comfort to patients who may not tolerate standard dialysis due to their health conditions. CRRT is administered more gradually than traditional dialysis, which helps reduce stress on critically ill patients.
In August 2024, Baxter International Inc., a U.S.-based healthcare company known for producing medical products, acquired The Carlyle Group Inc. for $3.8 billion. This acquisition allows Carlyle Group to strengthen its portfolio in renal care, positioning itself to capitalize on the increasing demand for innovative dialysis products and services for patients with chronic kidney disease. The Carlyle Group Inc. is a U.S.-based investment firm with a focus on continuous renal replacement therapy.
Major companies operating in the continuous renal replacement therapy market are Medtronic Plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Toray Industries Inc., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, NxStage Medical Inc., Gambro AB, JMS Co. Ltd., Quanta Dialysis Technologies Ltd., Bellco S.r.l., Ningbo Tianyi Medical Devices Co. Ltd., Kawasumi Laboratories Inc., Medica S.p.A., Infomed SA, Nikkiso Co. Ltd., Anjue Medical Equipment Co. Ltd., Toray Medical Co. Ltd., Kawasumi Hemofiltration Inc.
North America was the largest region in the continuous renal replacement therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the continuous renal replacement therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the continuous renal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The continuous renal replacement therapy (CRRT) market consists of revenues earned by entities by providing services such as acute hemodialysis, aquapheresis, and fluid management. The market value includes the value of related goods sold by the service provider or included within the service offering. The continuous renal replacement therapy market also includes sales of dialysis catheters, dialysates, hemostatic agents, and airway clearance systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Continuous Renal Replacement Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses continuous renal replacement therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for continuous renal replacement therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The continuous renal replacement therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.